Protein tyrosine phosphatases as novel targets in breast cancer therapy

Breast cancer is linked to hyperactivation of protein tyrosine kinases (PTKs), and recent studies have unveiled that selective tyrosine dephosphorylation by protein tyrosine phosphatases (PTPs) of specific substrates, including PTKs, may activate or inactivate oncogenic pathways in human breast canc...

Full description

Saved in:
Bibliographic Details
Published in:Biochimica et biophysica acta 2013-12, Vol.1836 (2), p.211-226
Main Authors: Nunes-Xavier, Caroline E., Martín-Pérez, Jorge, Elson, Ari, Pulido, Rafael
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - therapeutic use
Breast cancer
Breast Neoplasms - drug therapy
Cell signaling
Drug targeting
Female
Humans
Molecular Targeted Therapy
Protein Kinase Inhibitors - therapeutic use
Protein tyrosine kinase
Protein tyrosine phosphatase
Protein-Tyrosine Kinases - antagonists & inhibitors
Therapy resistance
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer is linked to hyperactivation of protein tyrosine kinases (PTKs), and recent studies have unveiled that selective tyrosine dephosphorylation by protein tyrosine phosphatases (PTPs) of specific substrates, including PTKs, may activate or inactivate oncogenic pathways in human breast cancer cell growth-related processes. Here, we review the current knowledge on the involvement of PTPs in breast cancer, as major regulators of breast cancer therapy-targeted PTKs, such as HER1/EGFR, HER2/Neu, and Src. The functional interplay between PTKs and PTK-activating or -inactivating PTPs, and its implications in novel breast cancer therapies based on targeting of specific PTPs, are discussed. [Display omitted]
ISSN:0304-419X
0006-3002
1879-2561
DOI:10.1016/j.bbcan.2013.06.001